Cetrotide (cetrorelix) / EMD Serono - LARVOL DELTA

Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles (clinicaltrials.gov) - P=N/A | N=160 | Not yet recruiting | Sponsor: Assiut University

New trial • Infertility • Sexual Disorders

Radix Bupleuri Chinensis Extract Ameliorates Doxorubicin-Induced Spermatogenic Dysfunction: Involvement of the GnRHR Signaling Pathway and Taurine Biosynthesis. (PubMed, Pharmaceuticals (Basel)) - "Background: Male infertility, largely driven by declining sperm quality, is a growing global concern. The in vivo cetrorelix experiments support the involvement of the GnRHR signaling pathway, whereas the concurrent changes in taurine, CDO1, and FMO1 are consistent with enhanced taurine biosynthesis. These findings provide experimental support for further investigation of CH as a potential intervention for chemotherapy-related reproductive injury."

Journal • Infertility • Sexual Disorders

Silicon-Based Highly c‑Axis-Oriented Strontium Barium Niobate Films with Large Pockels Coefficients. (PubMed, ACS Omega) - "Furthermore, the extracted Pockels coefficient r 33 of highly c-axis-oriented SBN75 films reached a maximum value of 431.3 pm/V, which is 10 times larger than that in lithium niobate (LN). The aforementioned findings make SBN75 a promising candidate for compact and high-speed electro-optic modulators."

Journal

Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers. (PubMed, Protein Sci) - "In aggregation assays, the multimeric variants inhibited Aβ42 aggregation at concentrations at which the monomeric form was no longer effective, with the SB175 trimer performing best. These results show how multimerization can be used to enhance the recognition of Aβ42 oligomers and offer a route toward diagnostic and therapeutic agents for Alzheimer's disease and other protein misfolding disorders."

Journal • Alzheimer's Disease • CNS Disorders • Proteinopathy • Aβ42

PPOS: Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Ahmed Saad

New P1/2 trial • Infertility • Sexual Disorders

Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI (clinicaltrials.gov) - P1 | N=189 | Not yet recruiting | Sponsor: Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)

Head-to-Head • New P1 trial • Gynecology • Infertility • Sexual Disorders

Evaluating progestin-primed and GnRH antagonist ovarian stimulation protocols in PGT-A cycles: implications for clinical practice. (PubMed, BMC Pregnancy Childbirth) - "PPOS and GnRH antagonist protocols yield comparable embryological and clinical outcomes in PGT-A cycles, including in advanced maternal age and diminished ovarian reserve subgroups. With its shorter stimulation duration and cost-effectiveness, PPOS is a valid alternative when fresh transfer is not planned."

Journal

Headache During IVF Treatment: A Comparative Evaluation of GnRH Agonist and Antagonist Protocols (EAN 2026) - " Infertile women undergoing IVF/ICSI were retrospectively evaluated by protocol, with recombinant FSH stimulation and recorded headache reports, including post-cetrorelix events A total of 46 women undergoing IVF were included in the analysis (GnRH agonist: n = 18; GnRH antagonist: n = 28)... Headache is more frequently reported during IVF cycles using GnRH antagonist protocols compared with agonist protocols. The early onset of symptoms following antagonist administration may be related to acute hormonal changes, rather than the ovarian stimulation process itself."

Clinical • Gynecology • Infertility

Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation syndrome: A cross-sectional study. (PubMed, Int J Reprod Biomed) - "The likelihood was 20 times higher for the 0.5 mg TDS group (adjusted odds ratio = 19.92, 95% CI [1.99, 199.04]) and 79 times higher for the 0.5 mg BID group (adjusted odds ratio = 79.29, 95% CI [9.31, 675.43]). In individuals with elevated risk, 0.75 mg TDS luteal-phase cetrorelix more effectively decreases OHSS risk and reduces hospitalizations compared to lower dosages."

Journal • Observational data • Infertility • Sexual Disorders

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov) - P3 | N=266 | Recruiting | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: Jun 2029 ➔ Jul 2028 | Trial primary completion date: Oct 2028 ➔ Jul 2028

Trial completion date • Trial primary completion date • Infertility • Sexual Disorders

Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats. (PubMed, AAPS PharmSciTech) - "Serum exposure was substantially reduced after intranasal administration, minimizing systemic distribution. This study demonstrates, for the first time, that cetrorelix-loaded Chi-Plx nanoparticles can efficiently deliver peptide drugs to the brain via the intranasal route, offering a promising, needle-free strategy to enhance patient compliance and reduce adverse effects in GnRH-related therapies."

Journal • PK/PD data • Preclinical

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis. (PubMed, J Coll Physicians Surg Pak) - "The cumulative probability ranking results showed that, for improving clinical pregnancy rate (CPR), leuprorelin (97.8%) ranked highest, followed by cetrorelix (70.7%), triptorelin (47.9%), buserelin (18.2%), and ganirelix (15.3%). For patients with the primary goal of improving CPR or LBR, leuprorelin is the more appropriate choice. Key Words: Polycystic ovary syndrome, Infertility, GnRH agonist, GnRH antagonist, Assisted reproduction."

Clinical • Journal • Retrospective data • Infertility • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Bedaya Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2026 ➔ Aug 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Infertility • Sexual Disorders

The antidiabetic potential of Leuconostoc mesenteroides strain SB1075 fermented soy yoghurt: Insights from mouse intestinal transcriptomics and metabolite analyses. (PubMed, Food Res Int) - "Collectively, these findings suggest that fermentation of SB1075-fermented soy yoghurt enhances the functional metabolite profile and may contribute to improved glycaemic regulation in diabetic mice. However, further studies involving targeted validation and clinical investigations will be required to confirm these mechanistic insights and evaluate the translational potential of SB1075-fermented soy yoghurt as a functional dietary intervention for metabolic health."

Journal • Preclinical • IL6 • IR

Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI (clinicaltrials.gov) - P2/3 | N=200 | Completed | Sponsor: Beni-Suef University | Not yet recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ Apr 2026 | Trial primary completion date: Sep 2023 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date

Medroxyprogesterone acetate vs. GnRH antagonist for preventing premature LH surge during ovarian stimulation in assisted reproductive technology: a retrospective cohort study. (PubMed, Front Reprod Health) - "To compare the effectiveness of medroxyprogesterone acetate (MPA) vs. cetrorelix (GnRH antagonist) in preventing premature LH surge during ovarian stimulation in assisted reproductive technology (ART) cycles, including cycles for intracytoplasmic sperm injection (ICSI) and fertility preservation...Cancellation, fertilization, and miscarriage rates did not differ significantly. MPA is a safe and effective oral alternative to GnRH antagonists for LH suppression during ovarian stimulation in ART, providing comparable reproductive outcomes while reducing treatment burden."

Journal • Retrospective data

The Stimulating Effect of Low-Molecular-Weight Luteinizing Hormone Receptor Agonist on Steroidogenesis and Ovulation in Female Rats with Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome. (PubMed, Int J Mol Sci) - "Taking into account differences in progesterone levels, cohorts with high (PCOS(H)) and low (PCOS(L)) progesterone were formed and treated with Follimag and Cetrotide. In both cohorts, TP03 and hCG increased progesterone levels and the expression of steroidogenesis (Star, Cyp11a1) and ovulation (Cox2, Adamts1, Egr1) genes, as well as inducing CL formation. Thus, TP03, like hCG, stimulates steroidogenesis and ovulation in PCOS-rats with different progesterone levels, which provides the first evidence of the effectiveness of allosteric LHR agonists as ovulation triggers in PCOS."

Journal • Preclinical • Polycystic Ovary Syndrome • ADAMTS1 • EGR1 • STAR

A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle. (PubMed, Theriogenology) - "The objective was to test the hypotheses that treatment with a GnRH antagonist, cetrorelix, in combination with progesterone will i) induce synchronous emergence of a new follicular wave and ovulation in cattle at random stages of the ovarian cycle, and ii) result in a pregnancy rate similar to that of an estradiol-based protocol. Pregnancy rates were not different (P ≤ 0.48) between treatment groups in Experiment 1 (Cetrorelix 78.9%, Estradiol 68.4%) or Experiment 2 (Cetrorelix 42.5%, Estradiol 45.3%). We conclude that a simple cetrorelix-based synchronization protocol is effective in heifers and suckling beef cows, and is a viable alternative to estradiol-based protocols."

Journal

PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (clinicaltrials.gov) - P=N/A | N=626 | Active, not recruiting | Sponsor: Mỹ Đức Hospital | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2025 ➔ Jun 2026

Enrollment closed • Trial primary completion date

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov) - P3 | N=333 | Recruiting | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

Hydrogel and Oleogel Formulation of the Decapeptide Cetrorelix Acetate for nasal Administration. (PubMed, Eur J Pharm Sci) - "Pharmacokinetic studies after nasal administration to male Wistar rats showed peptide absorption from both formulations over 24 hours with different kinetics (oleogel: Cmax = 14.1 ± 9.9 ng/ml, tmax = 1.0 ± 0.5 h, AUC0→24h = 33.0 ± 12.67 ng/ml; hydrogel: Cmax = 10.3 ± 0.8 ng/ml, tmax = 4.0 ± 2.0 h, AUC0→24h = 217.6 ± 8.6 ng/ml). The hydrogel formulation yielded a relatively high absolute bioavailability after nasal administration of 5.3 % compared to subcutaneous (s.c.) administration, thus making it interesting for further development."

Journal

Massive Small Bowel Resection Induces IFALD-Like Liver Injury in Mice. (PubMed, Yonago Acta Med) - "Serum biochemistry and liver histology were compared between the Sham, SBS50 (SBS murine model by performing 50% small bowel resection), SBS75 (SBS murine model by performing 75% small bowel resection), and SBS90 groups...At POD14, the liver histology demonstrated macrovesicular steatosis with minimal inflammatory infiltration, whereas SBS90 mice evaluated on POD28 exhibited macrovesicular steatosis together with severe portal and periportal inflammatory cell infiltration. This reproducible severe SBS mouse model enabled early and time-dependent hepatic injury evaluation following massive intestinal resection, providing a platform for studying IFALD-contributing mechanisms."

Journal • Preclinical • Gastrointestinal Disorder • Hepatology • Immunology • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Short Bowel Syndrome

Targeting angiogenesis in endometriosis: a systematic review and network meta-analysis of VEGF-directed pharmacotherapies. (PubMed, Front Reprod Health) - "Curcumin achieved the greatest lesion-size reduction (SMD = -1.08, 95% CI = -1.38 to -0.79) and the steepest fall in microvascular density (-16%), while cetrorelix most effectively reduced lesion number (SMD = -0.78, 95% CI = -1.36 to -0.20). Retinoic acid and bevacizumab halved VEGF expression...These findings are best viewed as hypothesis-generating and may assist in prioritising agents for more rigorous translational and clinical research, rather than supporting specific treatment recommendations. PROSPERO CRD420251082905."

Journal • Retrospective data • Endometriosis • Gynecology • Pain • Women's Health • AKT1 • CASP3 • MAPK1 • STAT3

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (clinicaltrials.gov) - P3 | N=204 | Not yet recruiting | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

IVF ART: Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles. (clinicaltrials.gov) - P4 | N=230 | Not yet recruiting | Sponsor: Trust Fertility Clinic

First-in-human • Head-to-Head • New P4 trial